Sporadic inclusion body myositis (or IBM) is part of the inflammatory myopathy group. The immune system goes awry and attacks the organism’s own elements, the muscles in particular: it’s an autoimmune disease. Normally, the immune system protects the organism against alien elements or external aggressors. In autoimmune diseases, it reacts to components from its own organism (autoimmune reaction). Various immune mechanisms are involved according to the type of myositis.
BYM338 study
- Reference laboratory: Institute of Myology
This randomised, pivotal, dose-finding, multicentric, placebo-controlled, double blind, parallel, phase IIb/III study aims at evaluating the efficacy, safety and tolerability of intravenous BYM 338 at 52 weeks on physical function, muscular strength and mobility as well as the long-term safety (up to 2 years) on patients affected with sporadic inclusion body myositis.
RAPAMI study
- Reference laboratory: Institute of Myology
This prospective, randomised, controlled, double blind, monocentric, phase IIb trial evaluating rapamycine against placebo aims at evaluating the effect of Rapamycine on muscular strength and the immune response during inclusion body myositis.
For further information: RAPAMI study webpage
CBYM338B2203E1 study
- Reference laboratory: Institute of Myology
This extension of the CBYM338B2203 Phase IIb/III study aims at evaluating the long-term efficacy, safety and tolerability of intravenous BYM 338 in patients with sporadic inclusion body myositis.
For further information: CBYM338B2203E1 study webpage
